Your browser doesn't support javascript.
loading
From MAFLD to hepatocellular carcinoma and everything in between / 中华医学杂志(英文版)
Chinese Medical Journal ; (24): 547-556, 2022.
Article in En | WPRIM | ID: wpr-927546
Responsible library: WPRO
ABSTRACT
Metabolic (dysfunction) associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most common cause of chronic liver disease worldwide. Many risk factors contribute to the pathogenesis of MAFLD with metabolic dysregulation being the final arbiter of its development and progression. MAFLD poses a substantial economic burden to societies, which based on current trends is expected to increase over time. Numerous studies have addressed various aspects of MAFLD from its risk associations to its economic and social burden and clinical diagnosis and management, as well as the molecular mechanisms linking MAFLD to end-stage liver disease and hepatocellular carcinoma. This review summarizes current understanding of the pathogenesis of MAFLD and related diseases, particularly liver cancer. Potential therapeutic agents for MAFLD and diagnostic biomarkers are discussed.
Subject(s)
Full text: 1 Index: WPRIM Main subject: Risk Factors / Carcinoma, Hepatocellular / Non-alcoholic Fatty Liver Disease / Liver Neoplasms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Chinese Medical Journal Year: 2022 Type: Article
Full text: 1 Index: WPRIM Main subject: Risk Factors / Carcinoma, Hepatocellular / Non-alcoholic Fatty Liver Disease / Liver Neoplasms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Chinese Medical Journal Year: 2022 Type: Article